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ABSTRACT 
 
Background and purpose: NF-B driven inflammation is negatively regulated by the zinc 
finger protein, A20. Gibberellic acid (GA3) is a plant-derived diterpenoid with documented 
anti-inflammatory activity, which is reported to induce A20-like zinc finger proteins in 
plants. Here, we sought to investigate the anti-inflammatory effect of GA3 in airway 
epithelial cells and determine if the anti-inflammatory action relates to A20 induction.  
 
Experimental approach: Primary nasal epithelial cells (n=7), and a human bronchial 
epithelial cell line (16HBE14o-) were used.  Cells were pre-incubated with GA3 (30M, 1h), 
stimulated with Pseudomonas aeruginosa LPS (10g/ml), IL-6 and IL-8 release, A20, NF-
B and IκBexpression determined. To determine if any observed anti-inflammatory effect 
occurred via an A20-dependent mechanism, A20 was silenced using siRNA.  
 
Key results: GA3 pre-incubation significantly induced A20 mRNA (4h) and protein (24h), 
resulting in a significant reduction in IL-6 and IL-8 release. This effect was mediated via 
reduced IκB degradation and reduced NF-B (p65) expression. Furthermore, the anti-
inflammatory action of GA3 was abrogated in A20-silenced cells.  
 
Conclusions and implications: Here we show that A20 induction by GA3 attenuates 
inflammation in airway epithelial cells, at least in part through its effect on NF-B and IB. 
GA3 or gibberellin-derived derivatives could potentially be developed into anti-inflammatory 
drugs for the treatment of chronic inflammatory diseases associated with A20 dysfunction. 
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INTRODUCTION 
The airway mucosa is under constant attack from invading pathogens, which are recognised 
by pattern recognition receptors (PRR) on the surface of airway epithelial cells and 
circulating immune cells. Toll-like receptor 4 (TLR4) recognises the LPS component of 
Gram-negative bacterial cell walls. Activation of TLR4 triggers an innate immune response 
leading to an acute inflammatory response that is largely mediated by the transcription factor 
NF-B. Following receptor-ligand binding with the plasma membrane, the intracellular 
stages of the NF-B signalling cascade are tightly regulated to ensure timely termination of 
the inflammatory response. A20 (TNFAIP3, (tumour necrosis factor, alpha-induced protein 
3)) is an endogenous negative regulator of NF-B signalling that is rapidly and transiently 
induced in response to bacterial and viral stimuli. A20 terminates NF-κB driven inflammation 
in response to LPS by inhibiting the polyubiquitination and activation of the central adaptor 
protein TNF receptor-associated factor (TRAF)6 (Lin et al. 2008).  
In the lung, Gram-negative Pseudomonas aeruginosa (P. aeruginosa) challenge 
rapidly induces A20 in mice (Tiesset et al. 2009), while A20 is essential for termination of 
TLR2/4 mediated IL-8 release from primary airway epithelial cells (Gon et al. 2004). 
Furthermore, A20 protects against ovalbumin (OVA)-induced ‘asthma’ in mice (Kang et al. 
2009).   Li et al. (2013) showed that A20 is involved in antigen degradation by facilitating the 
fusion between the endosome and lysosome, resulting in reduced antigenicity upon 
absorption of the antigen. We recently demonstrated that A20 is significantly reduced in the 
chronically inflamed Cystic Fibrosis (CF) airway epithelium and that basal mRNA 
expression correlates strongly with lung function (FEV1 % predicted) in people with CF 
(Kelly et al. 2013a, 2013b). In addition to observations in the airways, A20 is known to be 
important in the pathogenesis of various inflammatory diseases (rheumatoid arthritis, 
systemic lupus erythematosus, Type 1 Diabetes, multiple sclerosis, psoriasis, colitis, chronic 
inflammatory bowel disease and Crohn’s disease), where it may also serve as a susceptibility 
gene and biomarker of disease development (Martin and Dixit 2011, Barmada et al. 2004, 
Wellcome Trust Case Consortium 2007). A20 knockout in epithelial cells promotes severe 
mucosal inflammation (Vereecke et al. 2011). The therapeutic potential of targeting the A20 
gene and resulting protein has been widely recognized but a therapeutic agent is not currently 
available.   
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Although a critical regulator of mammalian immune responses, A20-like zinc finger 
proteins are also important in controlling plant stress responses. Liu et al. reported that 
gibberellic acid (GA3), a tetracyclic diterpene, induces A20-like zinc finger proteins in rice 
crops (Liu et al. 2011). Interestingly, GA3 has previously been used in the treatment of human 
lung cancer and in a rodent model of diabetes, and was shown to exert anti-inflammatory and 
analgesic effects (Miklussak et al. 1980, Muthuraman and Srikumar 2009). Furthermore, a 
recently developed gibberellin derivative possesses potent anti-tumor and anti-angiogenic 
activity in various tumour derived cell lines (Zhang et al. 2012). Gibberellins comprise a 
large family of tetracyclic diterpenoid plant hormones biosynthesized via ent-kaurene 
intermediates, which have diverse biological roles in plant growth and development. In 
plants, gibberellins play signalling roles in responses to environmental changes (temperature, 
stress and light) and are involved in the control of stem and root elongation, leaf expansion, 
seed germination and flowering (Yamaguchi 2008). Many terpenes, including diterpenes, 
triterpenes, and sesquiterpenes, possess anti-inflammatory activity both in vivo and in vitro. 
Furthermore, most terpenes inhibit NF-κB activity, although the precise mechanisms of 
action have not been fully characterized. In particular, forskolin has been used successfully in 
the treatment of asthma to reduce inflammation and histamine release through activation of 
cAMP-dependent mechanisms (Huerta et al. 2010). In the case of kaurenes, Castrillo et al. 
(2001) have identified relevant targets for this inhibition, showing that the inhibition of NIK 
(NF-κB inducing kinase, non-canonical NF-B pathway) and p38 and/or ERK1 and ERK2 
activation abrogates the inflammatory response, of genes dependent on NF-κB activation in 
particular. The fact that kaurenes are intermediates in the biosynthesis of plant hormones, 
such as gibberellins, offers the possibility of envisaging further analysis of the interaction of 
these molecules in several aspects of mammalian cell biology (Castrillo et al. 2001). 
Several gibberellin-based preparations are under patent for the treatment of diabetes 
(Patent reference US 20050215496 A1), psoriasis and prostatitis (Patent reference WO 
1991008751 A1), highlighting the increasing interest in developing gibberellins for pre-
clinical and clinical trials. However, gibberellins have not yet been used clinically as anti-
inflammatory drugs and the mechanism of action has not been reported. Here, we seek to 
investigate if GA3 can induce A20 and thereby reduce the innate inflammatory response to 
bacterial LPS in airway epithelial cells (16HBE14o- and primary nasal epithelial cells).  
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EXPERIMENTAL PROCEDURES 
 
Cell Culture 
The immortalised bronchial epithelial cell line 16HBE14o- (obtained from D. Gruenert 
UCSF, USA) was grown as described (Kelly et al. 2013c). Primary nasal epithelial cells 
(NEC) were obtained from healthy volunteers (n=7) and grown as previously described (de 
Courcey et al. 2012). The participants did not have any acute airways disease at the time of 
sampling, or a history of any chronic airways inflammation. The study was approved by the 
Research Ethics Committee of Northern Ireland (07/NIR02/23) and all participants provided 
informed consent (de Courcey et al. 2012). 
 
Cell culture stimulations 
All cells were treated with LPS (P. aeruginosa, Sigma-Aldrich, 10 g/ml) for up to 24 h. 
Cells were exposed to a range of GA3 concentrations (Sigma- Aldrich, G7645, lot 
BCBB9751, 3–300 µM) or dexamethasone (Dex, Sigma-Aldrich, D4902, lot BCBH2988V, 1 
µM) for 1 h prior to LPS stimulation.  
 
Determination of LPS induced cytokine release (IL-6 and IL-8) 
The concentrations of IL-6 and IL-8 in cell-free culture supernatants were measured by a 
commercially available ELISA (PeproTech EC Ltd., UK) according to the manufacturer’s 
instructions.  
 
LDH Cytotoxicity assay 
The effect of GA3 on membrane integrity was determined by quantification of lactate 
dehydrogenase (LDH) in cell culture supernatants (LDH-Cytotoxicity Assay Kit, BioVision 
Ltd. USA) according to the manufacturer’s instructions.  
 
Proliferation Assay 
Cell proliferation was determined using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, UK) following 72h exposure to GA3 and according to the 
manufacturer’s recommendations. The assay determines the activity of mitochondrial 
NAD(P)H-dependent oxidoreductases, which reduces the tetrazolium dye MTS (3-(4,5-di-
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methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) to 
insoluble purple formazan, which is measured at =490 nm.  
 
Transfection studies 
Transfections were performed at 70–80% confluency. A20 was silenced in 16HBE14o- cells 
using a commercially available human A20 siRNA (GenomeWide siRNA, Qiagen) and 
RNAiFect™ Transfection Reagent (Qiagen). Experiments included mock (transfection 
reagent only) and scrambled (Allstars Neg siRNA, Qiagen) controls. A20 knockdown was 
confirmed by qPCR (transfection efficiency over 70%) and Western Blot. 
 
RNA extraction and real time qPCR 
Total RNA was extracted using an RNeasy kit (Qiagen) and quantified on a Nanodrop 
(Thermo Scientific). Equal amounts of RNA were reverse transcribed into cDNA (Sensiscript 
Reverse Transcription Kit, Qiagen). Primers were designed using gene accession numbers 
and Primer3 open-source PCR primer design software and obtained from Invitrogen Ltd. 
(Paisley, UK). Quantitative PCR was performed using a LightCycler rapid thermal cycler 
system (Roche Diagnostics Ltd, UK). Multiple house-keeping genes were tested and -actin 
chosen for consistency within cycles and between different samples. 
Expression of A20, p65 and -actin (housekeeping gene) were assessed by qPCR. All 
primer sequences are given in Table S1. Relative expression to β-actin was calculated using 
the ΔΔCt method. To overcome inter-patient variability in basal gene expression levels in 
NECs, mRNA expression after LPS stimulation (24h) was compared with mRNA expression 
at 0h (standardized to 1) for each individual sample. cDNA obtained from Jurkat cells acted 
as an internal calibrator for all experiments and was used to determine differences in basal 
gene expression. 
 
Western Blotting 
Protein expression was determined by Western Blotting after extraction of total proteins in 
RIPA buffer. Cell lysates were diluted in nuclease free water and Laemmli loading buffer, 
loaded onto Tris-HCl polyacrylamide gels (Thermo Scientific), separated by SDS-PAGE and 
transferred to a PVDF membrane. Membranes were incubated with 1 µg/ml primary 
antibodies (Ber-A20 (Hirsch et al. 2012), A20 C-terminal (IMGENEX, IMG-161A), p65 
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(Santa Cruz Biotechnology, C-20), IkB (Santa Cruz Biotechnology, C-21) washed, 
incubated with appropriate horseradish peroxidase-conjugated secondary antibodies (Thermo 
Scientific, UK) and visualized on a BioRadChemi Doc XRS system.  
 
P65 activation ELISA 
Nuclear protein was extracted from 16HBE14o- cells using the Ne-Per™ assay (Thermo 
Scientific, cat no.78833). Total protein was determined in the extracts using the BCA protein 
assay (Pierce, cat no. 23225) and equal amounts nuclear protein (10 g) were used in the p65 
activation ELISA (Activ Motif, TransAM®, NF-B Family Transcription factor Assay kit, 
Cat no. 43296). Briefly, each ELISA well contains the immobilized NF-B consensus site 
(5’-GGGACTTTCC-3’) to which active NF-κB binds. The primary antibody (here anti-p65) 
can only bind to the epitope on the active p65 that is bound to its target DNA. Then an HRP-
conjugated secondary antibody is used to provide a sensitive colorimetric readout that is 
sprectrophotometrically quantified. All assays were performed according to the 
manufacturer’s instructions. 
 
Statistical analysis  
All data are presented as the means ± SEM. Differences between groups were analysed using 
the Kruskal-Wallis non-parametric ANOVA, which was considered to be significant if 
p < 0.05. Dunn’s post-test was performed if the Kruskal Wallis test was significant. To assess 
the effect of GA3 pre-treatment on LPS stimulated PNECs, Willcoxon paired T-test was 
applied. Statistical significance levels are indicated as *p<0.05, **p<0.01 and ***p<0.001. 
GraphPad Prism was used to plot graphs and to analyse the data. 
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RESULTS 
 
Changes in gene or protein expression are shown relative to the corresponding untreated 
control. Given the limited amount of material available from primary cultures, all primary 
NEC investigations were performed at the mRNA level initially and confirmed at the protein 
level where possible.  
 
Effect of GA3 pre-treatment on cellular viability and LPS-stimulated cytokine release  
In the first instance, we sought to determine an optimal non-cytotoxic GA3 dose that would 
also induce significant anti-inflammatory effects. Therefore, the effect of various GA3 
concentrations (0.03–300 M) on cellular viability and LPS-stimulated IL-6 and IL-8 release 
was investigated in the bronchial epithelial cell line 16HBE14o-. 
LDH release into cell culture supernatants was analysed 24 h after GA3 treatment and 
used as a measure of cytotoxicity. GA3 concentrations of 0.03–30 M did not increase LDH 
release above the vehicle control, while 300 M GA3 caused a significant increase in LDH 
release (p<0.001, n=6; Fig 1A). IL-8 release was significantly increased compared with 
untreated cells following 24 h LPS stimulation (Fig 1B). In 16HBE14o- cells, GA3 treatment 
alone did not have any effect on basal IL-8 release, but GA3 pre-treatment significantly 
reduced the LPS-induced IL-8 release in a dose-dependent manner with a significant 
reduction at 30 M (p<0.01, n=5-9) (Fig 1B). The maximal effective concentration to reduce 
IL-8 was 28.19 M, while a reduction of 40% was achieved at 2.82 M (Fig 1C). Similarly, 
GA3 treatment alone did not have any effect on basal IL-6 release, but GA3 pre-treatment 
significantly reduced the LPS induced IL-6 release with a significant reduction at 30 M 
(p<0.05, n=5-8) (Fig 1D).  
Based on these results and previous publications, a concentration of 30 M GA3 was 
employed in all further experiments. For comparative purposes, the anti-inflammatory effect 
of dexamethasone (Dex, 1 µM), was also investigated (Fig 1B, D). IL-8 and IL-6 release 
from 16HBE14o- cells pre-treated with Dex prior to LPS stimulation displayed significantly 
lower levels of each cytokine than cells treated with LPS alone (p<0.001 for both cytokines, 
n=5) or GA3 and LPS (p<0.05 for both cytokines, n=5). 
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Our initial experiments in 16HBE14o- cells were confirmed in primary nasal 
epithelial cells (PNECs). PNECs were pre-treated with GA3 (3-300 M) for 1 h before LPS 
was added to the cultures for a further 24 h. GA3 concentrations of 0.3–300 M did not 
increase LDH release above the vehicle control, but 300 M GA3 caused a significant 
increase in LDH release compared to 0.3 M and 3 M (p<0.01 and p<0.05, respectively, 
n=6; Fig 2A).  In PNECs, LPS treatment significantly increased IL-8 and IL-6 release 
(p<0.05 and p<0.01 respectively, n=7), (Fig 2B-1 and Fig 2C-1), while GA3 pre-treatment 
significantly reduced it (p=0.019 and p=0.008, Wilcoxon (paired t-test, n=7) at 24 h (Fig 2B-
2 and Fig 3C-2).  
 
GA3 promotes an A20-driven, anti-inflammatory response in 16HBE14o- cells 
LPS stimulation of 16HBE14o- cells resulted in the rapid and transient induction of A20 
mRNA with peak expression observed after 1 h. Thereafter, A20 expression slowly declined 
and returned to basal levels 4 h after LPS stimulation (Fig 3A). This is consistent with the 
original findings of Opipari et al. (1990). GA3 pre-treatment (30 M) alone significantly 
induced A20 mRNA expression compared to culture medium control (1 h, p<0.05). The 
subsequent addition of LPS further enhanced and prolonged the induction of A20 mRNA 
compared to culture medium control (1 h and 4 h, p<0.001, 24 h, p<0.05,), LPS alone (4 h, 
p<0.05) or GA3 alone (1 h and 4 h, p<0.05) and A20 expression remained above basal levels 
in GA3 pre-treated cells even 24 h after LPS treatment (Fig 3A, n=5-9). A20 mRNA 
expression was not induced in 16HBE14o- cells treated with Dex, prior to LPS stimulation 
(Fig 3A). 
Furthermore, analyses of p65 mRNA expression showed a significant induction of 
p65 by LPS alone (p<0.001, 4 h vs. Medium Control, n=5-9, Fig 3B) and GA3 pre-treated 
16HBE14o- show a significant reduction of LPS-induced p65 (p<0.001, 4 h vs. Medium 
Control, n=5-9, Fig 3B), suggesting that GA3 negatively affects the NF-κB pathway. Pre-
treatment of 16HBE14o- cells with Dex also attenuated LPS-induced p65 expression; 
however, this effect was not significant (Fig 3B). 
To investigate if the observed induction of A20 and the subsequent reduction in p65 
by GA3 is responsible for the anti-inflammatory effects outlined in Fig 1B and 2B-1, 
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16HBE14o- cells were treated with siRNA targeting A20. Fig 3C shows that when A20 is 
silenced in 16HBE14o- cells, the anti-inflammatory effect of GA3 on LPS-induced IL-8 
release is lost (p<0.001, n=5, Fig 3C). These experiments suggest that GA3 acts in an A20-
dependent manner.  
 
GA3 induces A20 mRNA and protein in PNECs 
To investigate the effect of GA3 on A20 in PNECs, cells were pre-treated with GA3 (30 M) 
for 1 h before the addition of LPS to the cultures and incubated for a further 24 h. In non-
stimulated cells, A20 mRNA levels remained unchanged over the duration of the experiment 
(data not shown). When cells were stimulated with LPS for up to 24 h, A20 mRNA levels 
increased significantly over culture medium control (p<0.01, n=7) with a peak expression at 
4 h (Fig 4A). GA3 exposure alone induced A20 mRNA in PNECs in a time-dependent 
manner (p<0.05, 24 h vs. culture medium control, n=7, Fig 4A). In GA3 pre-treated cells, LPS 
(10 g/ml) increased A20 mRNA levels significantly over medium control (n=7 with 
p<0.001 at 4 h and p<0.01 at 24 h). GA3 pre-treated and LPS stimulated PNECs also showed 
a significant increase in A20 mRNA compared to LPS alone at 4 h (p<0.05, n=7, Fig 4A). In 
Dex pre-treated and LPS stimulates 16HBE14o- no significant induction of A20 mRNA was 
observed n=5). A20 protein expression (24 h after LPS challenge) was determined by 
Western Blotting and quantified. In accordance with mRNA levels, A20 protein was induced 
by GA3 in PNECs challenged with LPS (p<0.05, compared to GA3, n=6, Fig 4B).  
Using an antibody against the C-terminal end of A20 that has been previously used to 
identify A20 cleavage products (http://www.novusbio.com/primary-antibodies/tnfaip3). We 
show that GA3-dependent induction of A20 in PNECs results in an up-regulation of the 
whole A20 protein: The representative blot and the quantification in Fig 4C (n=4) shows C-
terminal A20 protein bands with a molecular weight of the expected 80 kD (whole protein) 
and those with approximately 60 kD and 50 kD corresponding to C-terminal A20 fractions 
containing zinc finger 1-2 (~50 kD) and zinc finger 1-3 (~60 kD) (Klinkenberg et al. 2001). 
The antibody also detects a C-terminal A20 fraction of around 40 kD, although bands of this 
size were not detected in this study. Incubation with GA3 in the presence or absence of LPS 
leads to an increase of all protein bands in similar proportions (Fig 4C). Only in GA3 and 
LPS treated cells, the 60 kD band, corresponding to zinc finger 1 to 3, was significantly 
increased compared to control cells (p<0.05, n=4, Fig 4C).  
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GA3 reduces LPS induced cytokine release via reduction of NF-κB (p65) 
We and others have previously shown that IL-8 production in epithelial cells is largely 
dependent on p65 activation (Dommisch et al. 2010, Kelly et al. 2013b). To investigate if 
GA3 affects NF-B signalling, p65 mRNA was analysed 1, 4 and 24 h after LPS challenge in 
GA3 pre-treated PNECs. LPS significantly induced p65 mRNA expression compared to 
culture medium control at 1 h and 4h (p<0.05 and <0.001, n=7). However, p65 mRNA was 
significantly reduced in GA3 treated PNECs 4 h after LPS challenge (p<0.05, n=7) (Fig 5A). 
Dex pre-treatment of PNECs and subsequent LPS stimulation, similar to pre-treatment with 
GA3, resulted in a significant reduction of p65 mRNA 4h after stimulation (p<0.05, n=5) 
(Fig 5A).  
LPS induced NF-B (p65) activation starts with the posttranslational modification 
e.g. by phosphorylation of p65 (phosphorylation on serine 536), in the cytosol and is then 
translocated into the nucleus (Hall et al. 2006). Having shown a reduction of p65 mRNA by 
GA3 treatment, we further confirmed that GA3 exerts its anti-inflammatory action via 
modulation of NF-B activation. Firstly, the level of nuclear activated NF-B (p65) was 
significantly induced by stimulation with LPS at 15 min returning to culture medium control 
levels at 24h (p<0.001 and p<0.01, n=5, Fig 6A). GA3 pre-treated and LPS stimulated 
16HBE14o- showed significantly reduced nuclear active p65 at 15 min compared to LPS 
stimulation alone (p<0.05, n=5, Fig 6A). Dex pre-treatment also reduced p65 activity 15 min 
after LPS stimulation (p<0.01, n=5, Fig 6A).  
Secondly, phosphorylation of p65 on serine 536 was determined in whole cells 
(cytosolic and nuclear) extracts in 16HBE14o- by Western Blotting. Our results indicate a 
reduction of the phosphorylation on serine535 in GA3 pre-treated cells for up to 8 h after LPS 
challenge (Fig 6B). 
Finally, we investigated key events in the pathway upstream of p65 in 16HBE14o- 
cells. LPS-mediated activation of NF-B is reliant on the activation and subsequent 
degradation of IkB We determined cytosolic IB protein expression in PNECs and show 
that LPS treatment significantly reduces cytosolic IB (p<0.05), while treatment with GA3 
restored in part IB protein levels (p=0.05) (all n=6, Fig 6C). 
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Overall these results confirm an anti-inflammatory effect of GA3 in LPS stimulated 
airway epithelial cells. This appears to be mediated, in part at least, by the induction of A20 
(mRNA and protein) and subsequent inhibition of key stages in the NF-κB pathway. 
 
 
 
DISCUSSION  
 
The cytoplasmic zinc finger protein A20 is a central negative regulator of NF-κB that 
governs multiple intracellular pathways. Here, we report that pre-incubation of LPS-
stimulated airway epithelial cells (16HBE14o- cells and PNECs) with GA3, significantly 
induces A20 mRNA and protein. Although GA3 alone also induced A20 mRNA, this did not 
result in a detectable increase in protein, suggesting that GA3 mainly enhances LPS-induced 
A20 expression. Maximal induction of mRNA was slightly delayed in PNECs compared to 
16HBE14o- cells (1 h vs. 4 h), which could be explained by the differences in the cell types 
(16HBE14o- is a SV immortalized cell line (Kelly et al. 2013c), whereas PNECs are primary 
cells cultured for up to 3 passages). Furthermore, the induction of A20 was accompanied by a 
significant increase in IBlevels and subsequent reduction in NF-B expression and IL-6 
and IL-8 release in both cell lines and primary epithelial cells. Silencing of A20 confirmed 
that the reduction in IL-8 release was A20 dependent. 
El-Mofty et al. suggested that GA3 had carcinogenic effects and lead to tumour formation in 
Swiss Albino mice (El-Mofty et al. 1994). However, we tested GA3 at a range of 
concentrations from 0-300 M and found no evidence of cellular toxicity or increased 
proliferation even at 3 or 30 M (Figure S1, Supplement). The proliferation assay was 
conducted over 72 h to ensure at least one complete cell cycle had taken place. In our hands 
the doubling time of 16HBE14o- cells is approximately 28 h. 
Our results are in line with data by Kasamatsu et al. (2012), who showed that 
incubating adipose-derived stem cells with GA3 (1 mM) did not alter cell morphology or 
viability. Early work by Miklussák et al. (1980) suggested that administration significantly 
improves metabolic functions in patients with lung cancer. More recently, Zhang et al. (2012) 
showed that the gibberellin derivative 3-chlorine-3,15-dioxy-gibberellic acid methyl ester 
(GA-13315), possessed potent antitumor and antiangiogenic activity in vitro and in vivo.  
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LPS activation of the NF-B pathway is dependent on the ubiquitination and 
subsequent proteasomal degradation of TRAF6 (Mabilleau et al. 2011). This process frees 
bound signalling molecules for subsequent downstream events including the activation of 
NEMO, degradation of cytosolic IκB and translocation of NF-B subunits to the nucleus. 
NF-κB is sequestered in the cytoplasm, bound by members of the IκB family of inhibitor 
proteins, which includes IκB. IKK phosphorylates IκB, resulting in its K48-linked 
ubiquitination and subsequent proteasomal degradation.  This then allows translocation of the 
NF-κB subunits p65/p50 to the nucleus to activate target genes. To address where GA3 acts in 
the NF-κB pathway, we show a significant reduction in cytosolic IκBprotein in LPS 
stimulated cells, suggesting that it has been degraded to release the NF-κB subunits to the 
nucleus. GA3 treatment inhibits the LPS induced degradation of IκB, which may explain the 
anti-inflammatory effect seen (reduced IL-8 and IL-6 release and p65 mRNA). Furthermore, 
we show that GA3 treatment leads to reduced p65 nuclear activity (Fig 6A) and this is 
associated with decreased phosphorylation of p65 on serine 536 (Fig 6B).   
Information about the induction of A20 is still controversial. A20 has been described 
as being NF-κB dependent, and da Silva et al. (2012a) showed that this activation of the 
‘anti-inflammatory arm of NF-κB’ is associated with reduced expression of phosphorylated 
(ser536) p65 compared to the induction of phosphorylated (ser536) p65 by TNFalone. 
Similarly, we show here that in bronchial epithelial cells the induction of A20 by GA3 pre-
treatment leads to a reduction in the expression of phosphorylated (ser536) p65 compared to 
LPS stimulated cells (Fig. 6B) suggesting that the phosphorylation of p65 – e.g. by IKK 
kinases (Hall et al. 2006) – could be a target of A20. Our data on p65 nuclear activity (Fig. 
6A) may suggest that GA3 itself induces low levels of NF-B (although not statistically 
significant), but further phosphorylation states or DNA binding sites of p65 would need to be 
investigated. 
Finally, the A20 protein consists of an N-terminal OTU (Ovarian tumour) domain and 
a C-terminal domain that consists of 7 Cys-Cys zinc fingers. Work by Evans et al. (2004) 
assigned the DUB (deubiquitination) activity to the OTU domain whereas the anti-
inflammatory activity was in the zinc finger domain (especially zinc finger 4 and 7 have been 
identified to exhibit the anti-inflammatory effect of A20 (O’Reilly and Moynagh 2003, 
Dommisch et al. 2010, Tokunaga et al. 2012). Furthermore, De Valck et al. (1996) showed 
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that A20 zinc fingers have the ability to self-assemble to build the whole A20 zinc finger 
domain. To investigate if GA3 can induce the whole A20 protein we used two antibodies 
against full length A20 and the C-terminal domain specifically (O’Reilly and Moynagh 2003, 
Dommisch et al. 2010). Our data suggest that in PNECs, incubation with GA3 in the presence 
or absence of LPS leads to an increase of all protein bands in similar proportions representing 
the whole protein and the zinc finger domain of the A20 protein. However, in cells treated 
with GA3 and LPS the 60 kD fraction appeared to be increased compared to unstimulated 
cells. The 60 kD band has been described as zinc finger (ZF) 1-3 (~60 kD) (Klinkenberg et 
al. 2001) and our findings are in accordance with the description for this commercial A20 
antibody in THP1 cells (http://www.novusbio.com/primary-antibodies/tnfaip3). ZF 4 has 
been shown to facilitate the NF-B reducing anti-inflammatory action of A20 (Wertz et al. 
2004; Lu et al. 2013), but mice with a non-functional ZF4 showed that this domain might not 
be needed for the anti-inflammatory function of A20. In T cells MALT1 cleaves A20 into a 
37 kD and a 50 kD fraction (McAllister-Lucas and Lucas 2008; Malinverni et al. 2010), but 
to date this 60 kD band has not been further identified. 
The current study has some limitations: Firstly, the effect of GA3 on inflammatory 
mediators and the mechanism of its anti-inflammatory action have been investigated in cell 
culture, which may also impose several limitations. In most experiments we used an 
immortalised cell line (16HBE14o-). A characteristic of these cells is that they release IL-8 
and IL-6 throughout proliferation. This may explain why cytokine levels are already 
relatively high in untreated cells. Furthermore, compared to macrophages or monocytic cell 
lines, relatively high amounts of LPS are needed to stimulate airway epithelial cells and this 
is true for cell lines and primary cells alike. Another limitation of our study is that the effects 
of GA3 on p65 and IκB – although associated with A20 induction – have not been further 
validated using siRNA experiments. However, we do show that the anti-inflammatory effect 
of GA3 is directly dependent on the induction of A20, as GA3 has no effect on the release of 
inflammatory mediators in cells lacking A20 (knock down of A20 via siRNA, Fig. 3C). In 
PNECs, the number of experiments is limited by the low cell number available from nasal 
brushings and the fact that PNECs can only be expanded up to passage 3.  Due to the lack of 
PNECs our investigation of induction of zinc finger fractions was only performed four times, 
which may lead to an imperfect statistical estimation. Many products are known to contain 
trace amounts of LPS and small amounts of LPS may desensitize to a subsequent challenge. 
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The GA3 preparation used in this study passes the tests for plant cell culture applications 
(Sigma), but has not been specifically tested for its LPS content. However, determination of 
TLR4 mRNA in GA3 treated cells shows no change in the expression of TLR4 while in LPS 
stimulated cells TLR4 shows a time-dependent upregulation (Fig. S2, Supplement). Overall 
this may suggest that the GA3 preparation lacks TLR4 stimulating endotoxins. Finally, future 
work is required to determine if GA3 reduces pro-inflammatory cytokine secretion when cells 
are treated after LPS challenge.  
In summary, we describe that pre-incubation of airway epithelial cell lines and 
primary nasal epithelial cells with GA3 (single bolus of 30 M) induces the NF-B regulator 
A20 at mRNA and protein level thereby exerting an anti-inflammatory effect upon 
subsequent LPS stimulation. Our work provides molecular evidence (i) for A20 as a 
therapeutic target in inflammatory diseases and (ii) for the plant diterpenoid gibberellin in 
reducing NF-B driven inflammatory responses. Gibberellin or gibberellin-derived 
derivatives could be developed into anti-inflammatory drugs for the potential treatment of 
chronic inflammatory diseases associated with A20 dysfunction such as salivary gland 
degeneration (Kasamatsu et al. 2012), liver degeneration (da Silva et al. 2012b), bone 
resorption associated with inflammatory diseases (Shimada et al 2008, Mabilleau et al. 2011) 
and psoriasis (Gon et al. 2004, Kelly et al. 2012b). Furthermore, the concept of 
pharmacological induction of A20 presents A20 as a potential drug target to reduce or 
normalise the inflammatory response in chronic inflammatory airway diseases such as CF, 
asthma and COPD. Further work will investigate GA3 in primary cells from patients with 
chronic airways disease.  
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FIGURE LEGENDS 
 
Figure 1: Effect of GA3 on LDH and cytokine release from the bronchial epithelial cell 
line 16HBE41o-  
(A) 16HBE14o- cells were treated with GA3 for 24 h and LDH release into the culture 
medium determined. At 0.03, 0.3, 3 and 30 μM, GA3 did not cause any significant LDH 
release, while 300 μM caused a significantly higher LDH release (blue bars) when compared 
to vehicle controls (grey bar) (p<0.001, n=6). (B) 16HBE14o- bronchial epithelial cells were 
treated with GA3 (0.03 – 300 μM, 1 h), or Dexamethasone [Dex, 1 μM, 1 h]. LPS [10 μg/ml] 
was subsequently added to the cultures. Interleukin (IL)-8 release was determined by ELISA 
after 24 h. GA3 (3-300 μM) and Dex [1 μM] pre-treatment in LPS stimulated 16HBE14o- 
caused a significant reduction in IL-8 release (p<0.01, n=5-9). (C) The maximal effective 
concentration to reduce IL-8 (by 47%) was 28.19 M, while a reduction of 40% was 
achieved at 2.82 M (all green squares). (D) 16HBE14o- cells were treated with GA3 (0.03 - 
30 μM, 1 h), or Dexamethasone [Dex, 1 μM, 1 h] prior to LPS exposure [10 μg/ml]. IL-6 
release was determined by ELISA after 24 h. GA3 [30 μM] and Dex [1 μM] pre-treatment in 
LPS stimulated 16HBE14o- caused a significant reduction in IL-6 release (p<0.01, n=5-8). 
For figure B and D: medium control (grey), GA3 (blue), LPS (red), GA3+ LPS (purple), Dex 
(green)).  
 
 
Figure 2: Effect of GA3 on LDH and cytokine release from primary nasal epithelial cells 
(PNECs) 
(A) PNECs were pre-treated with GA3 (3 - 300 μM for 1 h) before LPS (10 μg/ml) was added 
to the cultures for 0-24h. Analysis of LDH in the supernatants showed no significant increase 
in LDH release (blue bars) above the vehicle control (grey bar) as a result of treatment with 
GA3. (B-1) LPS treatment significantly increased IL-8 release (p<0.05, n=8). (B-2) GA3 pre-
treatment [30 M, 1h] significantly reduced LPS-induced IL-8 release in PNECs (p<0.05, 
n=8) at 24 h. Consistently, (C-1) LPS treatment significantly increased IL-6 release (p<0.05, 
n=7), while, (C-2) GA3 [30 M, 1h] pre-treatment significantly reduced LPS-induced IL-6 
release in PNECs (p<0.05, n=7) after 24h exposure. For figure B and C: medium control 
(grey), GA3 (blue), LPS (red), GA3+ LPS (purple)).  
  
 
 
 
24 
Figure 3: Anti-inflammatory effect of GA3 in 16HBE14o- cells is A20 dependent. 
(A) 16HBE14o- bronchial epithelial cells were pre-treated with LPS [10 μg/ml] alone for 24 
h, or with GA3 [30 μM, 1h] or Dexamethasone [Dex, 1 μM, 1 h] prior to the addition of LPS 
[10 μg/ml] for a further 24 h, and A20 mRNA was determined by qPCR.  Both LPS and GA3 
treatment significantly induced A20 mRNA in 16HBE14o- cells (p<0.01 – 0.001, n=5-9). (B) 
p65 mRNA was significantly increased 4 h after LPS treatment (10 μg/ml, p<0.001, n=5-9). 
This effect was significantly attenuated when cells were pre-treated with GA3 [30 μM, 1h] 
(p<0.001, n=5-9). For figure A and B: medium control (grey), GA3 (blue), LPS (red), GA3+ 
LPS (purple), Dex (green)). (C) However, when A20 was silenced with siRNA, the anti-
inflammatory effect of GA3 (determined by IL-8 release of LPS stimulated cells (24 h)) is 
lost (p<0.001, n=5, Fig 3C).  
 
 
Figure 4: GA3 induces A20 mRNA and protein in PNECs 
PNECs were pre-treated with LPS alone [10 μg/ml], or pre-treated with GA3 [30 μM, 1 h] or 
Dexamethasone [Dex, 1 μM, 1 h] prior to the addition of LPS [10 μg/ml] to the cultures for 
0-24 h and A20 mRNA and protein expression investigated. GA3 (blue bars) induced (A) 
A20 mRNA in PNECs in a time-dependent manner, with a significant increase at 24 h (n=7, 
p<0.05: 24h vs. Medium Control (grey bar)). When cells were stimulated with LPS [10 
μg/ml] for up to 24 h (red bars), A20 mRNA levels increased significantly over Medium 
Control (grey bar) (p<0.05 and p<0.01, n=7). In GA3 [30 M] pre-treated cells, LPS [10 
μg/ml] increased A20 mRNA levels significantly (purple bar) over LPS alone (red bar) 
(p<0.05, n=7). Pre-treatment with Dex (green bar) did not significantly induce A20 mRNA 
(n=5). (B) Western Blot analysis confirmed an increase in A20 protein expression when cells 
were pre-treated with GA3 and then challenged with LPS (purple bar) (p<0.05, n=6, over 
GA3 alone (blue bar)). (C) Representative blot and quantification of Western Blots after use 
of IMG-161A, an antibody against the C-terminal end of A20 that can identify several zinc 
fingers. Incubation with GA3 in the presence or absence of LPS leads to an increase of all 
protein bands in similar proportions with the highest increase in the 50kD (zinc finger 1-2) 
band compared to medium control or LPS alone. Only in GA3 pre-treated and LPS treated 
cells the 60 kD band, corresponding to zinc finger 1 to 3, was significantly increased 
compared to control cells (p<0.05, n=4, Fig 4C). 
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Figure 5: GA3 suppresses p65 expression in PNECs 
PNECs were treated with LPS alone [10 μg/ml], or pre-treated with GA3 [30 μM, 1 h] or 
Dexamethasone [Dex, 1 μM, 1h] prior to the addition of LPS [10 μg/ml] for 1, 4 or 24 h. 
LPS-induced p65 expression (mRNA) was subsequently measured by qPCR and found to be 
significantly reduced in GA3 treated PNECs 4 h after LPS challenge (p<0.05, n=5-7). 
Medium control (grey), GA3 (blue), LPS (red), GA3+ LPS (purple), Dex (green)).  
 
 
Figure 6: Effect of GA3 is associated with reduced p65 and increased cytosolic IkBa  
(A) LPS induced activation of nuclear p65 was significantly reduced in GA3 pre-treated 
PNECs 4 h after LPS challenge (p<0.05, n=5). Medium control (grey), GA3 (blue), LPS 
(red), GA3+ LPS (purple), Dex (green)). (B) Phosphorylation of p65 on serine 536 was 
determined in whole cells extracts in 16HBE14o- by Western Blotting. Results indicate a 
reduction of the phosphorylation on serine535 in GA3 pre-treated cells for up to 8 h after LPS 
challenge. (C) Representative Blot and quantification of IkB protein expression in GA3 pre-
treated PNECs. LPS treatment (24 h) significantly reduces cytosolic IkBcompared to 
untreated and GA3 treated cells (p<0.05 and p<0.001, n=6). Pre-treatment with GA3 (1h 
before addition of LPS for 24h) restores in part cytosolic IkB protein levels (p<0.05, n=6). 
Medium control (grey), GA3 (blue), LPS (red), GA3+ LPS (purple)). 
 
 
 
